20.01.2016 • NewsElaine BurridgeNovozymescompany

Novozymes Separates Biopharma Activities

Danish biotechnology company Novozymes has separated its biopharma activities into an independent company called Albumedix. The new company will be headquartered in Lyngby, Denmark, with R&D and production facilities in Nottingham, UK. It will be fully owned by Novozymes and employ around 100 people.

Thomas Videbaek, Novozymes’ executive vice president for business development, said the business, which centers on developing recombinant albumin-based products and technologies, has great prospects and is now ready to be developed further outside Novozymes.

Albumin is a naturally occurring protein found in human blood. Albumedix’ recombinant albumins, branded Recombumin, are used in the pharmaceutical industry to stabilize drugs and vaccines. Albumin can also be used to extend the half-life of drugs to prolong their effect and Albumedix offers versions of this technology under the name Veltis.

The technology received its commercial breakthrough in 2014 when GlaxoSmithKline launched a diabetes treatment using Veltis, which allowed patients to dose weekly instead of daily.

The company said it currently has a growing pipeline of partner-driven drug candidates evaluating Veltis. Albumedix will also initiate the exploration of early stage clinical development based on Veltis and relevant drug candidates.

Peter Rosholm, who previously headed Novozymes’ biopharma business, has been appointed CEO of Albumedix. The leadership team will report to an independent board comprising three directors from the pharmaceutical industry and two representatives from Novozymes.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.